Catalent, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG00D0MX7G3
CTLT
Catalent, Inc.
GICS: 35202010
·
Sector: Healthcare
·
Sub-Sector: Drug Manufacturers—Specialty & Generic
NAME
Catalent, Inc.
ISIN
US1488061029
TICKER
CTLT
MIC
XNYS
REUTERS
CTLT.N
BLOOMBERG
CTLT US
F&G:
62
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Thu, 20.02.2025
Catalent
US1488061029
Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership.
Alessandro Maselli, President and CEO, and Board memb...
Catalent
Wed, 18.12.2024
Catalent
US1488061029
Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterpri...
Catalent
Sat, 14.12.2024
Catalent
US1488061029
Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now e...
Catalent
Fri, 06.12.2024
Catalent
US1488061029
Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the European Commission (EC) has granted unconditional approval for the pending transaction under which Novo Hold...
Catalent
Tue, 05.11.2024
Catalent
US1488061029
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the first quarter of fiscal 2025, which ended September 30, 2024.
“Our first quarter fiscal 2025 results reflect the continued momentum in our business and underscore our customers’ cont...
Catalent
Mon, 21.10.2024
Catalent
US1488061029
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers:
To Catalent’s Valued Customers,
I want to correct a few key inaccuracies that have been reported in the press regarding Novo Holdings’ pending acquisition of Catalent and...
Catalent
Mon, 14.10.2024
Catalent
US1488061029
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO...
Catalent
Thu, 29.08.2024
Catalent
US1488061029
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the fourth quarter of fiscal 2024, which ended June 30, 2024.
“I am pleased to report that Catalent ended our fiscal 2024 in a strong position, including growing non-COVID revenue by ne...
Catalent
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
